{"description":"The analysis included all participants receiving at least one vaccination and had at least one postvaccination follow-up visit.","eventGroups":[{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants did not continue to study Phase B.","id":"EG000","otherNumAffected":61,"otherNumAtRisk":79,"seriousNumAffected":0,"seriousNumAtRisk":79,"title":"GARDASIL 9 to 12 Years Old"},{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants did not continue to study Phase B.","id":"EG001","otherNumAffected":22,"otherNumAtRisk":29,"seriousNumAffected":0,"seriousNumAtRisk":29,"title":"GARDASIL 13 to 15 Years Old"},{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants did not continue to study Phase B.","id":"EG002","otherNumAffected":103,"otherNumAtRisk":119,"seriousNumAffected":1,"seriousNumAtRisk":119,"title":"GARDASIL 16 to 26 Years Old"},{"description":"Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants had the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.","id":"EG003","otherNumAffected":15,"otherNumAtRisk":19,"seriousNumAffected":0,"seriousNumAtRisk":19,"title":"Placebo 9 to 12 Years Old"}],"frequencyThreshold":"5","otherEvents":[{"organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":119,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Eye pain"},{"organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":119,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Myopia"},{"organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":79,"numEvents":8},{"groupId":"EG001","numAffected":2,"numAtRisk":29,"numEvents":3},{"groupId":"EG002","numAffected":8,"numAtRisk":119,"numEvents":8},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Abdominal pain"},{"organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG002","numAffected":2,"numAtRisk":119,"numEvents":4},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Dyspepsia"},{"organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":79,"numEvents":12},{"groupId":"EG001","numAffected":3,"numAtRisk":29,"numEvents":4},{"groupId":"EG002","numAffected":15,"numAtRisk":119,"numEvents":21},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Injection site erythema"},{"organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":79,"numEvents":113},{"groupId":"EG001","numAffected":20,"numAtRisk":29,"numEvents":46},{"groupId":"EG002","numAffected":88,"numAtRisk":119,"numEvents":188},{"groupId":"EG003","numAffected":9,"numAtRisk":19,"numEvents":21}],"term":"Injection site pain"},{"organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":79,"numEvents":37},{"groupId":"EG001","numAffected":8,"numAtRisk":29,"numEvents":9},{"groupId":"EG002","numAffected":31,"numAtRisk":119,"numEvents":48},{"groupId":"EG003","numAffected":4,"numAtRisk":19,"numEvents":7}],"term":"Injection site swelling"},{"organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":79,"numEvents":12},{"groupId":"EG001","numAffected":6,"numAtRisk":29,"numEvents":7},{"groupId":"EG002","numAffected":9,"numAtRisk":119,"numEvents":10},{"groupId":"EG003","numAffected":5,"numAtRisk":19,"numEvents":8}],"term":"Pyrexia"},{"organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":119,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Gastroenteritis"},{"organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79,"numEvents":3},{"groupId":"EG001","numAffected":2,"numAtRisk":29,"numEvents":2},{"groupId":"EG002","numAffected":2,"numAtRisk":119,"numEvents":2},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Malaria"},{"organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79,"numEvents":2},{"groupId":"EG001","numAffected":1,"numAtRisk":29,"numEvents":2},{"groupId":"EG002","numAffected":13,"numAtRisk":119,"numEvents":14},{"groupId":"EG003","numAffected":0,"numAtRisk":19,"numEvents":0}],"term":"Nasopharyngitis"},{"organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":3,"numAtRisk":119,"numEvents":3},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Upper respiratory tract infection"},{"organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG002","numAffected":3,"numAtRisk":119,"numEvents":3},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Dizziness"},{"organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":79,"numEvents":37},{"groupId":"EG001","numAffected":12,"numAtRisk":29,"numEvents":16},{"groupId":"EG002","numAffected":41,"numAtRisk":119,"numEvents":58},{"groupId":"EG003","numAffected":5,"numAtRisk":19,"numEvents":7}],"term":"Headache"},{"organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":119,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":19,"numEvents":1}],"term":"Somnolence"},{"organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG002","numAffected":11,"numAtRisk":119,"numEvents":16},{"groupId":"EG003","numAffected":0,"numAtRisk":19,"numEvents":0}],"term":"Dysmenorrhoea"}],"seriousEvents":[{"organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 16.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":119,"numEvents":1},{"groupId":"EG003","numAffected":0,"numAtRisk":19,"numEvents":0}],"term":"Foetal distress syndrome"}],"timeFrame":"Serious adverse events were assessed up to 19 months from study start. Other adverse events were assessed up to 15 days after each vaccination in study Phase A."}